Aberdeen Group plc Invests $1.22 Million in Myriad Genetics, Inc. $MYGN

Aberdeen Group plc purchased a new stake in Myriad Genetics, Inc. (NASDAQ:MYGN) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 229,593 shares of the company’s stock, valued at approximately $1,219,000. Aberdeen Group plc owned 0.25% of Myriad Genetics as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Janney Montgomery Scott LLC purchased a new stake in shares of Myriad Genetics during the 2nd quarter worth approximately $869,000. State of Alaska Department of Revenue grew its position in shares of Myriad Genetics by 8.9% in the second quarter. State of Alaska Department of Revenue now owns 54,911 shares of the company’s stock valued at $291,000 after purchasing an additional 4,469 shares during the period. Public Employees Retirement System of Ohio increased its stake in Myriad Genetics by 6,578.8% in the second quarter. Public Employees Retirement System of Ohio now owns 59,107 shares of the company’s stock valued at $314,000 after purchasing an additional 58,222 shares during the last quarter. Farther Finance Advisors LLC increased its stake in Myriad Genetics by 6,192.9% in the second quarter. Farther Finance Advisors LLC now owns 5,349 shares of the company’s stock valued at $28,000 after purchasing an additional 5,264 shares during the last quarter. Finally, Assenagon Asset Management S.A. lifted its position in Myriad Genetics by 285.2% during the second quarter. Assenagon Asset Management S.A. now owns 325,030 shares of the company’s stock worth $1,726,000 after buying an additional 240,643 shares during the period. Hedge funds and other institutional investors own 99.02% of the company’s stock.

Myriad Genetics Stock Performance

Shares of Myriad Genetics stock opened at $7.80 on Friday. Myriad Genetics, Inc. has a 1 year low of $3.76 and a 1 year high of $23.74. The firm’s 50-day simple moving average is $7.00 and its 200-day simple moving average is $6.09. The firm has a market cap of $725.75 million, a PE ratio of -1.82 and a beta of 1.97.

Myriad Genetics (NASDAQ:MYGN) last announced its quarterly earnings data on Tuesday, January 16th. The company reported ($0.19) earnings per share for the quarter. The firm had revenue of $156.40 million during the quarter. Myriad Genetics had a negative net margin of 47.45% and a negative return on equity of 5.17%. Myriad Genetics has set its FY23 guidance at ($0.33)-($0.28) EPS. On average, equities analysts predict that Myriad Genetics, Inc. will post -0.3 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Myriad Genetics in a report on Tuesday. Four investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $12.45.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.